Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Husam Alqaisi"'
Autor:
Esmail Al-Ezzi, Abhenil Mittal, Zachary W. Veitch, Amer Zahralliyali, Nely Mercy Diaz Mejia, Osama Abdeljalil, Husam Alqaisi, Vikaash Kumar, Aaron R. Hansen, Nazanin Fallah-Rad, Srikala S. Sridhar
Publikováno v:
Journal of Kidney Cancer and VHL, Vol 11, Iss 1 (2024)
Immunotherapy (IO) with or without targeted therapy (TT) is the standard treatment for patients with metastatic clear cell renal cell carcinoma (RCC). The evidence supporting their use in metastatic nonclear cell renal cell carcinoma (nccRCC) subtype
Externí odkaz:
https://doaj.org/article/b7d3d94769e84d84a091c0eecef9f662
Autor:
Esmail Mutahar Al-Ezzi, Abhenil Mittal, Zachary William Neil Veitch, Amer Zahralliyali, Nely Mercy Diaz Mejia, Osama Abdeljalil, Husam Alqaisi, Vikaash Kumar, Nazanin Fallah-Rad, Srikala S. Sridhar
Publikováno v:
Journal of Clinical Oncology. 41:636-636
636 Background: Immunotherapy (IO) with or without targeted therapy (TT) is the standard treatment for patients (pts) with advanced clear cell renal cell carcinoma. The evidence to support their use in metastatic non-clear cell renal cell carcinoma (
Autor:
Nely Mercy Diaz Mejia, Carlos Stecca, Di Maria Jiang, Nazanin Fallah-Rad, Philippe L. Bedard, Vikaash Kumar, Osama Abdeljalil, Amer Zahralliyali, Husam Alqaisi, Esmail Mutahar Al-Ezzi, Vivian Choy, Parmvir Banwait, Eshetu Atenafu, Srikala S. Sridhar
Publikováno v:
Journal of Clinical Oncology. 41:115-115
115 Background: To mitigate the risks of chemotherapy associated neutropenia, during the COVID-19 pandemic, all genitourinary (GU) cancer patients treated with chemotherapy at the Princess Margaret Cancer Centre (PMCC) were offered primary prophylaxi
Autor:
Husam Alqaisi, Stephanie Lheureux, Michelle McMullen, Jennifer J. Knox, Valerie Bowering, Crystal Lee, Rishi Chinta, Leslie Aguilar, Daniel McCormick, Ariel Chang, Chi-En Huang, Kasia Koziol, John Soong, Diane M. Provencher, Lee S. Rosen, Amit M. Oza
Publikováno v:
Journal of Clinical Oncology. 40:TPS5621-TPS5621
TPS5621 Background: Pre-clinical and clinical data demonstrate that CX-5461 selectively kills HR deficient cancer cells through stabilizing G4 structures and inducing replication-dependent DNA damage. Phase 1 studies suggest CX-5461 has clinical acti
Autor:
Ana Veneziani, Stephanie Lheureux, Husam Alqaisi, Gita Bhat, Ilaria Colombo, Eduardo Gonzalez, Sara Newton, Anthony Msan, Judy Quintos, Janelle Ramsahai, Robert C. Grant, Neesha C. Dhani, Lisa Wang, Valerie Bowering, Amit M. Oza
Publikováno v:
Journal of Clinical Oncology. 40:5505-5505
5505 Background: Platinum-resistant ovarian cancer (PROC) continues to have a poor prognosis. Maveropepimut-S (MVP-S, namely DPX-Survivac) leverages the lipid-based DPX delivery platform to educate a specific and persistent T cell-based immune respon
Autor:
Stephanie Lheureux, Husam Alqaisi, David E. Cohn, Jing-Yi Chern, Linda R. Duska, Andrea Jewell, Bradley Corr, Ira Seth Winer, Eugenia Girda, Marta A. Crispens, Neesha C. Dhani, Robert C. Grant, Saranya Uthayakumaran, Crystal Lee, Valerie Bowering, Horace Wong, Lisa Wang, Philippe L. Bedard, Jeffrey Moscow, Amit M. Oza
Publikováno v:
Journal of Clinical Oncology. 40:5514-5514
5514 Background: Mesothelin and its binder, antigen-CA125, are highly expressed in high grade serous and endometrioid ovarian cancers (HGOC) and, can inhibit paclitaxel-induced cell death. Anetumab ravtansine (AR) is a fully-human antibody directed a
Publikováno v:
Ann Transl Med
Pembrolizumab has previously shown antitumor activity against programmed death ligand 1 (PD-L1)-positive metastatic castration-resistant prostate cancer (mCRPC). Here, we assessed the antitumor activity and safety of pembrolizumab in three parallel c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29b80c3fc81e7a57296577183f3704b8
https://europepmc.org/articles/PMC7396782/
https://europepmc.org/articles/PMC7396782/
Publikováno v:
Journal of Clinical Oncology. 39:e18616-e18616
e18616 Background: PD-1/PD-L1 targeting monoclonal antibodies (mAbs) improve outcomes in multiple cancer types. Multiple mAbs are in clinical development, and many randomized control trials (RCTs) have been completed or are in progress. These RCTs co
Autor:
A. Zlotta, Robert J. Hamilton, Srikala S. Sridhar, Padraig Warde, Husam Alqaisi, Charles Catton, Nazanin Fallah-Rad, Adrian G. Sacher, Aaron R. Hansen, Neil Fleshner, Di Maria Jiang, Esmail Mutahar Al-Ezzi, Marco A. J. Iafolla
Publikováno v:
Annals of Oncology. 31:S537-S538
Autor:
Carlos Stecca, Sunil Samnani, Husam Alqaisi, Srikala S. Sridhar, Zachary William Neil Veitch, Jeenan Kaiser, Nimira S. Alimohamed, Scott North
Publikováno v:
Journal of Clinical Oncology. 39:412-412
412 Background: Patients with muscle-invasive bladder cancer (MIBC) historically have poor long-term outcomes, with nearly 50% developing metastatic disease. Similarly, patients with metastatic urothelial carcinoma (mUC) have had median overall survi